A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer
- 1 Clinical Oncology and Nuclear Medicine Department, University of Alexandria Faculty of Medicine, Alexandria, Egypt
- 2 Clinical Oncology and Nuclear Medicine Department, University of Alexandria Faculty of Medicine, Alexandria, Egypt
- 3 Clinical Oncology and Nuclear Medicine Department, University of Alexandria Faculty of Medicine, Alexandria, Egypt
- 4 Clinical Oncology and Nuclear Medicine Department, University of Alexandria Faculty of Medicine, Alexandria, Egypt
- 5 Preventive Medicine Division, University of Alabama at Birmingham, Birmingham, AL, USA
- 6 Hematology oncology Division, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC, USA
Abstract
Background: Randomized clinical trials have demonstrated the benefits of chemotherapy in carefully selected non-small cell lung cancer (NSCLC) pa tients. How generalizable these results are to other NSCLC patients is unresolved. Methods: The outcomes of patients treated with standard chemotherapy regimens (paclitaxel / carboplatin; gemcitabine / carboplatin; pemetrexed / car boplatin; paclitaxel / carboplatin / bevacizumab) off study as first line therapy between 2002 and 2012 at our institution were compared to the reported results of trials supporting the FDA approval of these drugs and/or regimens. Results: In our population, 38.1% of the patients had hypertension, 11.9% of the patients were diabetic, 23.7% had chronic obstructive pulmonary disease (COPD), 11.9% had coronary artery disease (CAD) and 2.1% had renal or liver disease. Notably, the presence of a single or multiple comorbidities was associated with low overall survival compared to matched patients with no comorbidities (p = 0.007). Conclusion: The presence of single or multiple comorbidities is associated with inferior overall survival compared to matched groups without such pre-existing conditions.
- Ferlay, J., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11.
- Jemal, A., et al. (2011) Global Cancer Statistics. CA: A Cancer Journal of Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107
- Beasley, M.B., Brambilla, E. and Travis, W.D. (2005) The 2004 World Health Organization Classification of Lung Tumors. Seminars in Roentgenology, 40, 90-97. https://doi.org/10.1053/j.ro.2005.01.001
- Travis, W.D., et al. (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology, 10, 1243-1260. https://doi.org/10.1097/JTO.0000000000000630
- DH, J. (1993) Chemotherapy for Metastatic Non-Small-Cell Lung Cancer Can That Dog Hunt. Journal of the National Cancer Institute, 85, 766-767. https://doi.org/10.1093/jnci/85.10.766
- Group, N.-S.C.L.C.C. (1995) Chemotherapy in Non-Small Celi Lung Cancer: A Meta-Analysis Using Updated Data on Individual Patients from 52 Randomised Clinical Trials. BMJ, 311, 899-909. https://doi.org/10.1136/bmj.311.7010.899
- Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J. and Johnson, D.H. (2002) Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 346, 92-100. https://doi.org/10.1056/NEJMoa011954
- Smit, E.F., et al. (2003) Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. Journal of Clinical Oncology, 21, 3909-3917. https://doi.org/10.1200/JCO.2003.03.195
- Ohe, Y., et al. (2007) Randomized Phase III Study of Cisplatin Plus Irinotecan versus Carboplatin Plus Paclitaxel, Cisplatin Plus Gemcitabine, and Cisplatin Plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan. Annals of Oncology, 18, 317-323. https://doi.org/10.1093/annonc/mdl377
- Hotta, K., et al. (2004) Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 3852-3859. https://doi.org/10.1200/JCO.2004.02.109
- McLeod, H.L., et al. (2000) Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034. Clinical Cancer Research, 6, 2677-2684.